De-risking Drug Development | Episode 4: Implement market launch strategy, pre-approval
De-risking Drug Development is a five-part podcast series that explores the business-critical decisions that take place at each stage of the drug development process. We know that novel therapies often don’t meet their revenue expectations, but through informed decision-making, you can minimize risk and maximize the probability of commercial success.
In episode 4, we focus on the pre-approval phase of drug development, where commercial launch planning should be started 2 - 3 years before marketing authorization. We discuss why it’s critical to start early, and highlight approaches that biotechs should implement, specifically those with a first-time launch. Our experts offer practical examples of how to build and embed launch excellence, focusing on actionable insight to mitigate risk at this stage in the product lifecycle.
Episode 1: Determine how to drive value in pre-clinical development
Episode 2: Focus on safety and efficacy and prove quickly that your product works
Episode 3: Plan how to get to market quickly, post-proof of concept
Episode 4: Implement market launch strategy, pre-approval
Episode 5: Expand the use and value of your product over time
Related Insights
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Case Study
Case Study Lifecycle maintenance
Nov 25, 2021
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Case Study
Case Study Marketing Authorization Transfer
Nov 25, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Related Insights
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Case Study
Case Study Lifecycle maintenance
Nov 25, 2021
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Three Ways Early-Stage Companies Can Attract Investors
Feb 3, 2022
Podcast
Funding Biotech Innovation: How to Attract Investors
Jan 18, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Video
Biotech Showcase: Fireside Chat with Jamie Macdonald
Jan 3, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Case Study
Case Study Marketing Authorization Transfer
Nov 25, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022